The MariTide trial evaluated once-monthly maridebart cafraglutide, a dual bispecific GLP-1 receptor agonist and glucose-dependent insulinotropic polypeptide (GIP) receptor antagonist, for the treatment of obesity.

Read Healio’s in-depth coverage of the MariTide trial . Enlarge

Researchers enrolled 592 adults with obesity or overweight plus one obesity-related complication who were randomly assigned to receive subcutaneous maridebart cafraglutide (MariTide, Amgen) or placebo.

The trial had two cohorts: patients obesity only and patients with obesity and type 2 diabetes.

At 1 year, maridebart cafraglutide was associated with significant reductions in body weight vs. placebo, regardless of diabetes status.

Results of the MariTide trial were presented at the American Diabetes Associati

See Full Page